Michael N L, Louie L G, Rohrbaugh A L, Schultz K A, Dayhoff D E, Wang C E, Sheppard H W
Division of Retrovirology, Walter Reed Army Institute of Research, Rockville, Maryland 20850, USA.
Nat Med. 1997 Oct;3(10):1160-2. doi: 10.1038/nm1097-1160.
Entry of human immunodeficiency virus type 1 (HIV-1) into target cells requires both CD4 (ref. 1, 2) and one of a growing number of G-protein-coupled seven-transmembrane receptors. Viruses predominantly use one, or occasionally both, of the major co-receptors CCR5 or CXCR4, although other receptors, including CCR2B and CCR3, function as minor co-receptors. CCR3 appears critical in central nervous system infection. A 32-base pair inactivating deletion in CCR5 (delta 32) common to Northern European populations has been associated with reduced, but not absolute, HIV-1 transmission risk and delayed disease progression. A more commonly distributed transition causing a valine to isoleucine switch in transmembrane domain I of CCR2B (64I) with unknown functional consequences was recently shown to delay disease progression but not reduce infection risk. Although we confirm the lack of association of CCR2B 64I with transmission, we cannot confirm the association with delayed progression. Although subjects with CCR5 delta 32 defects had significantly reduced median viral load at study entry, providing a plausible explanation for the association with delayed progression, this association was not seen with CCR2B 64I. Further studies are needed to define the role of CCR2B64I in HIV pathogenesis.
1型人类免疫缺陷病毒(HIV-1)进入靶细胞既需要CD4(参考文献1、2),也需要越来越多的G蛋白偶联七跨膜受体中的一种。病毒主要使用主要共受体CCR5或CXCR4中的一种,偶尔也使用两者,尽管其他受体,包括CCR2B和CCR3,作为次要共受体发挥作用。CCR3在中枢神经系统感染中似乎至关重要。北欧人群中常见的CCR5基因32碱基对失活缺失(delta 32)与HIV-1传播风险降低但并非完全消除以及疾病进展延迟有关。最近发现,CCR2B跨膜结构域I中一个更常见的导致缬氨酸变为异亮氨酸转换的突变(64I),其功能后果未知,但可延迟疾病进展但不降低感染风险。虽然我们证实CCR2B 64I与传播无关,但无法证实其与疾病进展延迟有关。尽管携带CCR5 delta 32缺陷的受试者在研究开始时病毒载量中位数显著降低,这为其与疾病进展延迟的关联提供了一个合理的解释,但CCR2B 64I并未出现这种关联。需要进一步研究来确定CCR2B64I在HIV发病机制中的作用。